Syngensys

Description

Syngensys develops synthetic gene promoters using transcriptional landscape analysis, computational design, selection, and validation to tailor expression systems for gene therapy, cell therapy, biomanufacturing platforms, and therapy manufacturing workflows.

Related

• TQ TherapeuticsTQ Therapeutics operates a CELLfinity platform that delivers in vivo cell and gene therapies using a proprietary EXiVO automated approach…
• VRG TherapeuticsVRG Therapeutics designs therapeutic miniproteins using a proprietary platform that combines AI-driven protein engineering with wet-lab…
• CircioCircio develops circular RNA and immunotherapy medicines, including circVec AAV gene therapy work that uses circular RNA to enhance…
• Oxford BiomedicaOxford Biomedica provides end-to-end CDMO services for cell and gene therapy clients, using lentivirus, AAV, and other viral vectors to…
• AAsgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
• BiosimulyticsBiosimulytics uses computational crystal structure prediction to map a molecule's solid-form landscape, predict competing polymorphs, and…
• Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
• NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
• Anacalypsis TherapeuticsAnacalypsis Therapeutics creates precision gene- and pathway-based therapeutic strategies, biomarkers, and genetically linked targets to…